Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax ...

The lithium companies will have to create a new royalty rate proposal, another delay for the commercial extraction of the ...

The Canadian healthcare-focused royalty company said Monday that the royalty interest in the worldwide net sales of all formulations of sebetralstat from KalVista Pharmaceuticals was acquired for an ...

Syndax has entered into a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of Niktimvo.

The lithium companies brought in an army of experts to make the case that their proposed royalty rate is on par with other ...

The stock was up 11% to $11.73 on Monday. Shares have jumped 37% over the past 12 months. The pharmaceutical company said the proceeds of the royalty financing deal will be used t ...

EMX Royalty (TSE:EMX) has released an update. EMX Royalty Corporation announces significant exploration successes at the ...

Provides Royalty Management with an equity interest and royalty stream from sales of patented products that serve the indoor farming and controlled agriculture spaces.Investment continues Company ...

On Monday, Royalty Pharma plc (RPRX) stock saw a modest uptick, ending the day at $27.2 which represents a slight increase of $0.10 or 0.37% from the prior close of $27.1. The stock opened at $27.52 ...

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through profitability; proforma cash approaching $800 mil ...